Milier Tüberküloz

Authors

Vildan Avkan Oğuz

References

Sharma SK, Mohan A. Miliary Tuberculosis. Microbiol Spectr. 2017; 5(2): 10.1128/microbiolspec.tnmi7-0013-2016. doi: 10.1128/microbiolspec.TNMI7-0013-2016.

Muzanyi G, Bark CM. Severe tuberculosis. Med Clin N Am 2025; 109: 641–650 https://doi.org/10.1016/j.mcna.2024.12.001

Kwong JS, Carignan S, Kang EY, Müller NL, FitzGerald JM. 1996. Miliary tuberculosis. Diagnostic accuracy of chest radiography. Chest 110:339–342.

Khan FY. Review of literature on disseminated tuberculosis with emphasis on the focused diagnostic workup. J Family Community Med. 2019 ;26(2): 83-91. doi: 10.4103/jfcm.JFCM_106_18.

Qui Y, Tang Y, Yu S, et al. Miliary Tuberculosis: A Comprehensive Review of Epidemiology, Clinical Manifestations, Diagnosis, Treatment, and Complications. Infect Drug Resist 2026; 19:616761. https://doi.org/10.2147/IDR.S616761

Halk Sağlığı Genel Müdürlüğü T.C. Sağlık Bakanlığı Tüberküloz Tanı ve Tedavi Rehberi; Avilable from: https://hsgm.saglik.gov.tr/depo/birimler/tuberkulozdb/Dokumanlar/Rehberler/Tuberkuloz_Tani_ve_Tedavi_Rehberi.pdf ( Ulaşım tarihi 2 Ağustos 2026)

Oztop A, Unsal I,Ozgu A, et al. Doksanbeş Erişkin Akciğer Dışı Tüberküloz Olgusu.Solunum Hast. 2004;15:34-42

Aysert Yıldız P, Karamanlioglu D, Ozger HS, et al. Extrapulmonary Tuberculosis: Clinical and Diagnostic Features and Risk Factors for Early Mortality. Acta Medica 2022; 53(4): 367-374. DOI: 10.32552/2022.ActaMedica.844

Mert A, Derin O, Zerdali E, et al. Epidemiological and clinical analysis, and outcomes of tuberculosis co-infection among people living with HIV in Türkiye (2014-2024) ClinSurv HIV cohort: A large case series. PLoS One. 2025 ;20(8):e0329267. doi: 10.1371/journal.pone.0329267.

Sharma SK,Mohan A, Sharma A. Challenges in the diagnosis & treatment of miliary tuberculosis. Indian J Med 2012; 135,:703-730

van Arkel C, Storms I, Kurver L, Smeenk F, et al. Elderly patients with tuberculosis in a low-incidence country – Clinical characteristics, inflammation and outcome. J Infect. Author manuscript. 2024 ;89(2):106200. doi: 10.1016/j.jinf.2024.106200.

Sharma SK, Mohan A, Sharma A. Miliary tuberculosis: A new look at an old foe. J Clin Tuberc Other Mycobact Dis. 2016; 3:13-27. doi: 10.1016/j.jctube.2016.03.003.

Lima LM, Aurilio RB, Fonseca AR, et al. Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review. Rev Paul Pediatr. 2023;42: e2022084. doi: 10.1590/1984-0462/2024/42/2022084.

DixonWG, HyrichKL, WatsonKD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Reg ister (BSRBR). Ann Rheum Dis. 2010; 69:522–528

Argüder E, Yanık Üstüner G, Ekici R,et al. Tuberculosis risk in patients with rheumatologic disease treated with biologic drugs. Tuberk Toraks 2020;68(3):236-244.

Cunha BA, Krakakis J, McDermott BP. Fever of unknown origin (FUO) caused by miliary tuberculosis: diagnostic significance of morning temperature spikes. Heart Lung 2009;38:77–82.

Flores-Franco RA, Ríos-Ortiz LA. The “damp shadow” sign: another clinical indicator of miliary tuberculosis. Heart Lung 2010; 39:87 88.

Mert A, Arslan F, Kuyucu T, et al. Miliary tuberculosis: Epidemiologicaland clinical analysis of large-case series from moderate to low tuberculosis endemic Country. Medicine (Baltimore). 2017;96(5): e5875. doi: 10.1097/MD.0000000000005875.

Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367(9517):1173-80. doi: 10.1016/S0140-6736(06)68507-3.

WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection, third edition. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO

WHO operational handbook on tuberculosis. Module 4: treatment and care. Geneva: World Health Organization; 2025. Licence: CC BY-NC-SA 3.0 IGO.

Nahid P, Dorman SE, Alipanah N, et al. Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e95. doi:10.1093/cid/ciw376

Thwaites GE, Nguyen DB, Nguyen HD,et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004 Oct 21;351(17):1741-51. doi: 10.1056/NEJMoa040573.

Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371 (12):1121–1130. doi:10.1056/NEJMoa1407380

Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. Aids. 2010;24(15):2381–2390. doi:10.1097/QAD.0b013e32833dfc68

Meintjes G, Scriven J, Marais S. Management of the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep. 2012;9(3):238–250. doi:10.1007/s11904-012-0129-5.

Taniguchi J, Aso S, Jo T, et al. Factors affecting in-hospital mortality in patients with miliary tuberculosis: A retrospective cohort study. Respir Investig. 2024;62(4):520-525. doi: 10.1016/j.resinv.2024.04.004

Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worlwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-80

Published

November 17, 2026

License

License